【摘要】慢性肾脏病患者常伴有不同程度的铁缺乏和铁代谢紊乱，铁调素、炎症、红细胞生成素、低氧诱导因子等参与上述过程。临床上将铁缺乏分为绝对性铁缺乏和功能性铁缺乏，铁调素、铁蛋白、转铁蛋白饱和度是评价和鉴别铁缺乏有效的指标。临床上合理选择和补充铁剂、降低铁调素水平、改善铁代谢紊乱对治疗慢性肾脏病铁缺乏非常重要。
【Abstract】Chronic kidney disease(CKD) patients are often accompanied by various degrees of iron deficiency and iron metabolism disorders; hepcidin, inflammation, erythropoietin and hypoxia-inducing factors are involved in the abnormalities. Iron deficiency can be classified into absolute iron deficiency and functional iron deficiency. Hepcidin, ferritin and transferrin saturation are useful markers to evaluate and diagnose iron deficiency. Clinically, rational use of iron supplements, reduction of hepcidin level, and improvement of iron metabolism are critical in the treatment of iron deficiency in CKD patients.
1. Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53(5):823-834.
2. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease. Acta Haematol. 2019;142(1):44-50.
3. Reichert CO, da Cunha J, Levy D, Maselli LMF, Bydlowski SP, Spada C. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol. 2017;137(4):220-236.
4. Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant. 2014;29(2):263-273.
5. Ueda N, Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients. 2018;10(9).
6. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-1594.
7. Kdoqi, National Kidney F. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11-145.
8. 李寒, 王世相. 维持性血液透析患者铁代谢状况的初步分析. 中国血液净化. 2010;9(09):482-485.
9. Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017;21 Suppl 1:S6-S20.
10. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275(26):19906-19912.
11. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705-5724.
12. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000;480(2-3):147-150.
13. Rishi G, Wallace DF, Subramaniam VN. Hepcidin: regulation of the master iron regulator. Bioscience reports. 2015;35(3).
14. Ginzburg YZ. Hepcidin-ferroportin axis in health and disease. Vitam Horm. 2019;110:17-45.
15. Ross SL, Tran L, Winters A, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012;15(6):905-917.
16. Panwar B, Gutierrez OM. Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease. Semin Nephrol. 2016;36(4):252-261.
17. Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl. 2015;26(1):19-25.
18. Zaritsky J, Young B, Wang HJ, et al. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1051-1056.
19. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012;7(7):e39783.
20. Petruliene K, Ziginskiene E, Kuzminskis V, Nedzelskiene I, Bumblyte IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas). 2017;53(2):90-100.
21. Santos-Silva A, Ribeiro S, Reis F, Belo L. Hepcidin in chronic kidney disease anemia. Vitam Horm. 2019;110:243-264.
22. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Tobolczyk J, Bodzenta-Lukaszyk A, Malyszko J. Iron Status and Inflammation in Early Stages of Chronic Kidney Disease. Kidney Blood Press Res. 2015;40(4):366-373.
23. Ribeiro S, Garrido P, Fernandes J, et al. Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells Mol Dis. 2016;59:63-70.
24. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-981.
25. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle. 2008;7(1):28-32.
26. Hayes W. Measurement of iron status in chronic kidney disease. Pediatr Nephrol. 2019;34(4):605-613.
27. Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39(2):130-141.
28. Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets. 2019;23(5):407-421.
29. Dhillon S. Roxadustat: First Global Approval. Drugs. 2019;79(5):563-572.
30. Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. N Engl J Med. 2019;381(11):1011-1022.
31. Chen N, Hao C, Peng X, et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. 2019;381(11):1001-1010.
32. Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis. Pharmaceuticals (Basel). 2019;12(4).
33. Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel). 2018;11(4).
